Open-house biologic discount agreements for abatacept
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-28 - Abatacept
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Multiple suppliers will be contracted; no guaranteed volume or revenue.
No estimated value provided; cannot assess revenue potential.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration until Nov 2027
- Conclusion of pharmaceutical rebate contracts under §130a Abs. 8 SGB V for the active substance Abatacept.
- Two lots based on dosage strength: 125mg and 250mg.
Show full summary
Open-House procedure for rebate contracts on Abatacept (two strengths: 125mg and 250mg) under German social law (§130a Abs. 8 SGB V). No estimated value provided. All suitable pharmaceutical companies can join at any time during the contract period (Dec 2025 – Nov 2027). No selection or award criteria beyond eligibility; all eligible participants get a contract. EU-funded flag is present but actual EU funding not confirmed.
Risks
Multiple suppliers will be contracted; no guaranteed volume or revenue.
No estimated value provided; cannot assess revenue potential.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) i.S.d. §4 Abs. 18 AMG.
- Must have a valid marketing authorization for the specific Abatacept product.
- A registered office in Germany, another EU member state, or EEA state (§9 Abs. 2 AMG).
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (2)
LOT-0001
Abatacept (Wirkstärke 125mg)
Rebate contract for Abatacept 125mg: Agreement with any eligible pharmaceutical company to provide rebates on the drug. Contract runs max 24 months from Dec 2025 to Nov 2027.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Abatacept im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
Value note
Show original TED data
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Abatacept im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
LOT-0002
Abatacept (Wirkstärke 250mg)
Rebate contract for Abatacept 250mg: Same terms as Lot 1 but for the 250mg strength.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Abatacept im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
Value note
Show original TED data
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Abatacept im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
Procurement Details
- Publication date
- 14 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 678563-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Multiple suppliers will be contracted; no guaranteed volume or revenue.
No estimated value provided; cannot assess revenue potential.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications